MCID: DMY001
MIFTS: 41

Demyelinating Polyneuropathy

Categories: Neuronal diseases, Rare diseases

Aliases & Classifications for Demyelinating Polyneuropathy

MalaCards integrated aliases for Demyelinating Polyneuropathy:

Name: Demyelinating Polyneuropathy 12 15
Peripheral Demyelinating Neuropathy 12 71

Classifications:



External Ids:

Disease Ontology 12 DOID:5214
NCIt 49 C27062
SNOMED-CT 67 23414001
UMLS 71 C0270922

Summaries for Demyelinating Polyneuropathy

MalaCards based summary : Demyelinating Polyneuropathy, also known as peripheral demyelinating neuropathy, is related to guillain-barre syndrome and multifocal motor neuropathy. An important gene associated with Demyelinating Polyneuropathy is PMP22 (Peripheral Myelin Protein 22), and among its related pathways/superpathways are Spinal Cord Injury and Cell adhesion molecules (CAMs). The drugs Prednisone and Glycine have been mentioned in the context of this disorder. Affiliated tissues include t cells, b cells and liver, and related phenotypes are behavior/neurological and homeostasis/metabolism

Related Diseases for Demyelinating Polyneuropathy

Diseases in the Demyelinating Polyneuropathy family:

Subacute Inflammatory Demyelinating Polyneuropathy Acute and Subacute Inflammatory Demyelinating Polyneuropathy
Chronic Acquired Demyelinating Polyneuropathy

Diseases related to Demyelinating Polyneuropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 409)
# Related Disease Score Top Affiliating Genes
1 guillain-barre syndrome 33.4 PMP22 HP ALB
2 multifocal motor neuropathy 31.5 FCGR2B CNTN2
3 polyneuropathy 31.4 TTR PMP22 NGF NFASC MAG CNTN2
4 polyradiculoneuropathy 31.3 PMP22 NFASC MAG CNTN1 ALB
5 sensory peripheral neuropathy 31.1 PMP22 NGF MAG ALB
6 mononeuritis multiplex 31.0 PMP22 MAG
7 mononeuropathy 31.0 PMP22 NGF MAG
8 chronic polyneuropathy 30.9 PMP22 MAG FCGR2B
9 miller fisher syndrome 30.8 PMP22 NFASC MAG CNTN1
10 autoimmune neuropathy 30.8 PMP22 NFASC MAG CNTN1
11 peripheral nervous system disease 30.7 TTR PMP22 NGF NFASC MAG ALB
12 median neuropathy 30.6 TTR PMP22
13 chronic graft versus host disease 30.4 TNFSF13B ALB
14 autoimmune peripheral neuropathy 30.3 NFASC MAG AIRE
15 autonomic neuropathy 30.2 TTR NGF ALB
16 meningoencephalitis 30.2 NGF CLDN5 ALB
17 neuromuscular disease 30.2 TNFSF13B PMP22 MAG ALB AIRE
18 malaria 29.4 TTR TNFSF13B HP FCGR2B CXCL9 ALB
19 kidney disease 29.1 TTR PTGDS HP APOA4 ALB
20 multiple sclerosis 28.9 TNFSF13B PTGDS NGF MAG CXCL9 CD52
21 peripheral demyelinating neuropathy, central dysmyelination, waardenburg syndrome, and hirschsprung disease 12.9
22 chronic acquired demyelinating polyneuropathy 12.5
23 subacute inflammatory demyelinating polyneuropathy 12.5
24 chronic inflammatory demyelinating polyradiculoneuropathy 12.5
25 acute and subacute inflammatory demyelinating polyneuropathy 12.4
26 guillain-barre syndrome, familial 12.3
27 lewis-sumner syndrome 11.7
28 neuropathy, hereditary, with liability to pressure palsies 11.6
29 charcot-marie-tooth disease, axonal, type 2e 11.5
30 mannosidosis, beta a, lysosomal 11.3
31 canomad syndrome 11.3
32 charcot-marie-tooth disease, axonal, type 2a1 11.3
33 charcot-marie-tooth disease and deafness 11.3
34 charcot-marie-tooth disease, type 4a 11.3
35 charcot-marie-tooth disease, x-linked dominant, 6 11.3
36 charcot-marie-tooth disease, x-linked dominant, 1 11.3
37 charcot-marie-tooth disease, x-linked recessive, 5 11.3
38 charcot-marie-tooth disease, axonal, type 2b 11.3
39 charcot-marie-tooth disease, demyelinating, type 1c 11.3
40 neuropathy, hereditary motor and sensory, type via, with optic atrophy 11.3
41 charcot-marie-tooth disease, type 4b1 11.3
42 charcot-marie-tooth disease, type 4d 11.3
43 charcot-marie-tooth disease, axonal, type 2d 11.3
44 charcot-marie-tooth disease, type 4c 11.3
45 charcot-marie-tooth disease, type 4b2 11.3
46 charcot-marie-tooth disease, axonal, type 2b1 11.3
47 charcot-marie-tooth disease, axonal, type 2b2 11.3
48 hereditary motor and sensory neuropathy, type iic 11.3
49 charcot-marie-tooth disease, dominant intermediate b 11.3
50 charcot-marie-tooth disease, axonal, type 2f 11.3

Graphical network of the top 20 diseases related to Demyelinating Polyneuropathy:



Diseases related to Demyelinating Polyneuropathy

Symptoms & Phenotypes for Demyelinating Polyneuropathy

MGI Mouse Phenotypes related to Demyelinating Polyneuropathy:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.9 AIRE APOA4 CNTN1 CNTN2 FCGR2B GAS6
2 homeostasis/metabolism MP:0005376 9.77 AIF1 AIRE ALB APOA4 FCGR2B GAS6
3 nervous system MP:0003631 9.4 AIF1 AIRE APOA4 CLDN5 CNTN1 CNTN2

Drugs & Therapeutics for Demyelinating Polyneuropathy

Drugs for Demyelinating Polyneuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 62)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
2
Glycine Approved, Nutraceutical, Vet_approved Phase 3 56-40-6 750
3 Pharmaceutical Solutions Phase 3
4 Immunoglobulin G Phase 3
5
rituximab Approved Phase 1, Phase 2 174722-31-7 10201696
6
Sargramostim Approved, Investigational Phase 1, Phase 2 123774-72-1, 83869-56-1
7
Methylprednisolone hemisuccinate Approved Phase 1, Phase 2 2921-57-5
8
Methylprednisolone Approved, Vet_approved Phase 1, Phase 2 83-43-2 6741
9
Lenograstim Approved, Investigational Phase 1, Phase 2 135968-09-1
10 Prednisolone acetate Approved, Vet_approved Phase 1, Phase 2 52-21-1
11
Prednisolone phosphate Approved, Vet_approved Phase 1, Phase 2 302-25-0
12
Prednisolone Approved, Vet_approved Phase 1, Phase 2 50-24-8 5755
13
Mesna Approved, Investigational Phase 1, Phase 2 3375-50-6 598
14
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
15
Prednisolone hemisuccinate Experimental Phase 1, Phase 2 2920-86-7
16 Trace Elements Phase 2
17 Vitamins Phase 2
18 Micronutrients Phase 2
19 Vitamin B Complex Phase 2
20 Nutrients Phase 2
21 Antioxidants Phase 2
22 Alpha-lipoic Acid Phase 2
23 Vitamin B9 Phase 2
24 Folate Phase 2
25 Thioctic Acid Phase 2
26 Autoantibodies Phase 2
27 Hormone Antagonists Phase 1, Phase 2
28 Hormones Phase 1, Phase 2
29 Anti-Inflammatory Agents Phase 1, Phase 2
30 Antineoplastic Agents, Hormonal Phase 1, Phase 2
31 glucocorticoids Phase 1, Phase 2
32 Protective Agents Phase 1, Phase 2
33 Antineoplastic Agents, Immunological Phase 1, Phase 2
34 polysaccharide-K Phase 1, Phase 2
35 Thymoglobulin Phase 1, Phase 2
36 Antibodies, Monoclonal Phase 1, Phase 2
37 Methylprednisolone Acetate Phase 1, Phase 2
38 Gastrointestinal Agents Phase 1, Phase 2
39 Antiemetics Phase 1, Phase 2
40 Neuroprotective Agents Phase 1, Phase 2
41 Antilymphocyte Serum Phase 1, Phase 2
42 Autonomic Agents Phase 1, Phase 2
43 Antibodies Phase 2
44 Immunoglobulins Phase 2
45 Immunologic Factors Phase 2
46 Rho(D) Immune Globulin Phase 2
47 Immunoglobulins, Intravenous Phase 2
48 gamma-Globulins Phase 2
49 Fibrinolytic Agents Phase 2
50 Plasminogen Phase 2

Interventional clinical trials:

(show all 41)
# Name Status NCT ID Phase Drugs
1 Treatment With Gamunex 10% Intravenous Immunoglobulin (IVIg) for Patients With Demyelination and Diabetes Mellitus: A Blinded, Placebo-Controlled Crossover Pilot Study Unknown status NCT02372149 Phase 4 10% intravenous immunoglobulin (IVIg);0.9% sodium chloride
2 Randomized Study of Single vs. Multiple Privigen Dose Regimens in Pediatric CIDP Recruiting NCT03684018 Phase 4
3 Prospective, Open-Label, Phase IIIb Study Evaluating the Safety, Tolerability and Efficacy of Panzyga® in Patients With Chronic Inflammatory Demyelinating Polyneuropathy Administered at Standard and High Infusion Rates Unknown status NCT03166527 Phase 3 Immune Globulin 10% Intravenous Solution
4 A Single-arm Study to Demonstrate the Efficacy and Safety of Privigen in the Treatment of Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT01184846 Phase 3
5 NPB-01(Intravenous Immunoglobulin) Maintenance Therapy for Patients With Chronic Inflammatory Demyelinating Polyneuropathy. Completed NCT01824251 Phase 3 NPB-01
6 Phase III Randomized, Double-Blind, Placebo-Controlled Study of 3,4-Diaminopyridine for Demyelinating Polyneuropathy Completed NCT00004939 Phase 3 ,4-diaminopyridine
7 Multicentre Randomized Open-label Trial to Compare Efficacy and Tolerance of Corticosteroids and IVIg in Patients With Chronic Inflammatory Demyelinating Polyneuropathy on a One Year Follow up Completed NCT01349270 Phase 3 Immunoglobulin perfusion;Prednisone
8 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT00004772 Phase 3 Immune globulin
9 Multicenter, Open-label Extension Study to Investigate the Long-term Safety and Efficacy of IgPro20 in Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Subjects Completing Study IgPro20_3003 Completed NCT02027701 Phase 3
10 Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase III Study to Investigate the Efficacy, Safety, and Tolerability of 2 Different Doses of IgPro20 (Subcutaneous Immunoglobulin) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - the PATH Study Completed NCT01545076 Phase 3
11 Phase III Multicenter Double Blind Controlled Trial of Human Immune Globulin Therapy in Previously Untreated Patients With Chronic Inflammatory Demyelinating Neuropathy Completed NCT00004286 Phase 3 immune globulin
12 Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of IGIV-Chromatography (IGIV-C), 10% Treatment in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT00220740 Phase 3 Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified;Albumin (Human) 25%, United States Pharmacopeia (USP)
13 SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study Unknown status NCT02967679 Phase 1, Phase 2 MD1003
14 Lipoic Acid for Chronic Inflammatory Demyelinating Polyneuropathy—A Randomized, Double-Blind, Placebo Controlled Pilot Study Completed NCT00962429 Phase 2 lipoic acid
15 The Efficacy of High-Dose Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT00001287 Phase 2 intravenous immunoglobulin (IVIg)
16 Safety, Tolerability, and Efficacy of Rituximab in Patients With Anti-Glycoconjugate Antibody-Mediated Demyelinating Neuropathy: A Double-Blind Placebo-Controlled Randomized Trial Completed NCT00050245 Phase 2 Rituximab
17 Intravenous Immunoglobulin Therapy for Small Fiber Neuropathy: a Randomized, Double-blind, Placebo-controlled Study on Efficacy and Safety. Completed NCT02637700 Phase 2 Intravenous Immunoglobulin;Placebo
18 The Evaluation of Efficacy and Safety of Rituximab (Genetical Recombination) in Refractory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patients With Immunoglobulin G4 (IgG4) Autoantibodies in the Exploratory Clinical Trial Recruiting NCT03864185 Phase 2
19 Non-myeloablative Autologous Hematopoietic Stem Cell Transplantation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy: A Phase II Trial Active, not recruiting NCT00278629 Phase 2
20 Non-myeloablative Hematopoietic Stem Cell Transplantation for Stiff Person Syndrome (SPS) and Anti-GAD Antibody Variants: Progressive Encephalomyelitis With Rigidity and Myoclonus (PERM), and Adult Onset Autoimmune Anti-GAD Positive Cerebellar Ataxia Active, not recruiting NCT02282514 Phase 1, Phase 2 Cyclophosphamide;Mesna;rATG;Methylprednisolone;G-CSF;Rituxan
21 Intravenous Immunoglobulin (IVIG) in the Treatment of Autoimmune Small Fiber Neuropathy Due to TS-HDS and FGFR-3 Antibodies: a Double Blinded Placebo-controlled Phase II Trial Not yet recruiting NCT04153422 Phase 2 Gammagard IVIG;Placebo
22 Thrombolysis in Ischemic Spinal Cord Stroke Terminated NCT02242084 Phase 2 Intravenuse Alteplase
23 Pilot Study of Acthar® Gel in Chronic Inflammatory Demyelinating Neuropathy Withdrawn NCT02574962 Phase 2 H.P. Acthar® Gel
24 A Phase II Trial of High-dose Cyclophosphamide for Moderate to Severe Refractory Chronic Inflammatory Demyelinating Polyneuropathy Withdrawn NCT01236456 Phase 2 Cyclophosphamide
25 Electromyography Evaluation of the Stabilizing Muscles of the Scapula and Tibial Anterior Muscle, After an Intervention Program by Proprioceptive Neuromuscular Facilitation in Muscle Force Irradiation. Unknown status NCT02255708 Phase 1
26 sCD163 & CD19 as Candidate Biomarkers in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - A Study of sCD163 in the Cerebrospinal Fluid Unknown status NCT02271724
27 sCD163 as a Potential Biomarker in Guillain- Barré Syndrome Unknown status NCT02582853
28 Effect of Resistance and Aerobic Exercise on Muscle Strength, Aerobic Capacity and Quality of Life in Patients Treated With Immunoglobulin for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) or Multifocal Motor Neuropathy (MMN) Completed NCT02121678
29 The Influence of Immunoglobulin Dosage and Administration on Development of Hemolytic Anemia and Variation on Muscle Strength in Patients With CIDP and MMN Completed NCT02111590 Immunoglobulins
30 Observational Study of the Prevalence of Some Genetic Mutations in Patients With Neuropathy Associated With Anti-Myelin-associated Glycoprotein (MAG) Antibodies. Completed NCT03268161
31 Prevalence of Decreased Corneal Sensation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT01379833
32 A Multicenter Pilot Study to Determine Criteria for Evaluating the Effectiveness of Two Comparative Monitoring Methods in the Management of Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Receiving Home-based Treatment With IVIg (Privigen®) Recruiting NCT03779828
33 A Multi-Site Tissue Repository Providing Annotated Biospecimens for Approved Investigator-Directed Biomedical Research Initiatives Recruiting NCT01931644
34 TTR-FAP Screening - Screening for the Transthyretin-Related Familial Amyloidotic Small Fiber Polyneuropathy - a International, Multicentre, Epidemiological Protocol Recruiting NCT01705626
35 Descriptive Analysis of Morphological Aspects of Nerve by Ultra-high Frequency Ultrasound (30-50MHZ) in Demyelinating Neuropathies: Inflammatory Demyelinating Polyneuropathy Chronic (IPDC), Neuropathy Multifocal Motor Block of Conducting (NMMBC) and Neuropathy With Antibody A MAG Recruiting NCT03008733
36 A Study of Subcutaneous Immunoglobulin as Chronic Treatment for Patients With Chronic Inflammatory Demyelinating Polyneuropathy Active, not recruiting NCT02465359 Immune Globulin Subcutaneous (Human)
37 Intravenous Immunoglobulin (IVIg) Treatment-Related Fluctuations in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patients Using Daily Grip Strength Measurements (GRIPPER) Active, not recruiting NCT02414490 Intravenous Immunoglobulin
38 Quantification of Nerve Stiffness in Patients With Peripheral Neuropathies Not yet recruiting NCT03397303
39 Study of Gait and Posture in Subacute Acquired Neuropathies and in Hereditary Neuropathies Not yet recruiting NCT04154540
40 Non-invasive Vagus Nerve Stimulation (nVNS) in Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Not yet recruiting NCT03772717 Standard of Care
41 Investigation of Plastic Changes in the CNS Associated With Peripheral Neuropathy Not yet recruiting NCT03805893

Search NIH Clinical Center for Demyelinating Polyneuropathy

Genetic Tests for Demyelinating Polyneuropathy

Anatomical Context for Demyelinating Polyneuropathy

MalaCards organs/tissues related to Demyelinating Polyneuropathy:

40
T Cells, B Cells, Liver, Skin, Bone, Kidney, Myeloid

Publications for Demyelinating Polyneuropathy

Articles related to Demyelinating Polyneuropathy:

(show top 50) (show all 2317)
# Title Authors PMID Year
1
Seronegative occult HBV reactivation complicated with fulminant acute liver failure after rituximab for chronic inflammatory demyelinating polyneuropathy. 61
31766959 2020
2
Combined intravenous immunoglobulin and methylprednisolone as induction treatment in chronic inflammatory demyelinating polyneuropathy (OPTIC protocol): a prospective pilot study. 61
31571349 2020
3
Unique HLA haplotype associations in IgG4 anti-neurofascin 155 antibody-positive chronic inflammatory demyelinating polyneuropathy. 61
31864140 2020
4
Comparative value and determinants of suitability of outcome measures in treated chronic inflammatory demyelinating polyneuropathy. 61
31650551 2020
5
Membrane property changes in most distal motor axons in chronic inflammatory demyelinating polyneuropathy. 61
31650564 2020
6
Low inter-rater reliability of brachial plexus MRI in chronic inflammatory neuropathies. 61
32012299 2020
7
Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE). 61
31558790 2020
8
Demyelinating Neuropathy Due to Intravascular Large B-cell Lymphoma. 61
31588080 2020
9
Nerve dysfunction leads to muscle morphological abnormalities in chronic inflammatory demyelinating polyneuropathy assessed by MRI. 61
31573095 2020
10
Patient-reported outcomes with subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: the PATH study. 61
31400231 2020
11
Acute inflammatory demyelinating polyneuropathy following interruption of antiretroviral treatment and HIV rebound. 61
31998944 2020
12
[Intravenous immunoglobulin-induced thrombocytopenia in patient with chronic inflammatory demyelinating polyneuropathy]. 61
31852869 2020
13
A model to predict the probability of acute inflammatory demyelinating polyneuropathy. 61
31751842 2020
14
Different distribution of demyelination in chronic inflammatory demyelinating polyneuropathy subtypes. 61
32006783 2020
15
Chronic inflammatory demyelinating polyneuropathy with tongue fasciculation: A case report. 61
31477466 2020
16
Diagnosis and treatment of Guillain-Barré Syndrome in childhood and adolescence: An evidence- and consensus-based guideline. 61
31941581 2020
17
Paraneoplastic demyelinating polyneuropathy associated with cardiac myxoma. 61
31587326 2020
18
Rituximab in refractory chronic inflammatory demyelinating polyneuropathy. 61
31922613 2020
19
Prospective study of the additional benefit of plexus magnetic resonance imaging in the diagnosis of chronic inflammatory demyelinating polyneuropathy. 61
31348848 2020
20
Progress in Hematopoietic Stem Cell Transplantation for CIDP. 61
32038107 2020
21
Immunoglobulin administration for the treatment of CIDP: IVIG or SCIG? 61
31765922 2020
22
Patients with chronic autoimmune demyelinating polyneuropathies exhibit cognitive deficits which might be associated with CSF evidence of blood-brain barrier disturbance. 61
32017808 2020
23
Nerve ultrasound improves detection of treatment-responsive chronic inflammatory neuropathies. 61
31959710 2020
24
Diagnostic accuracy of MRI and ultrasound in chronic immune-mediated neuropathies. 61
31827006 2020
25
Hyper-reflexia in Guillain-Barré syndrome: systematic review. 61
31937584 2020
26
Very early Guillain-Barré syndrome: A clinical-electrophysiological and ultrasonographic study. 61
31886449 2020
27
A case of combined central and peripheral demyelination in Zambia. 61
31958671 2020
28
Neuraxial Anesthesia and Lower Extremity Peripheral Nerve Blocks for Ankle Surgery in a Patient With Chronic Inflammatory Demyelinating Polyneuropathy: A Case Report. 61
31789825 2020
29
An update on clinical, pathological, diagnostic, and therapeutic perspectives of childhood leukodystrophies. 61
31829048 2020
30
Acute Neuromuscular Disorders in the Pediatric Intensive Care Unit. 61
31502491 2020
31
Nonsystemic vasculitic neuropathy in a patient with IgG-monoclonal gammopathy of undetermined significance: A case report. 61
32000451 2020
32
Demyelinating polyneuropathy in goats lacking prion protein. 61
31907995 2019
33
Near Real-Time Surveillance to Assess the Safety of the 9-Valent Human Papillomavirus Vaccine. 61
31740498 2019
34
Chronic inflammatory demyelinating polyneuropathy with anti-NF155 IgG4 in China. 61
31693967 2019
35
[Chronic inflammatory demyelinating polyneuropathy: Diagnosis and therapeutic update]. 61
31677862 2019
36
Chronic inflammatory demyelinating polyneuropathy: a rare cause of falls. 61
31796460 2019
37
Evaluation of Quality of Life in Patients With Chronic Inflammatory Demyelinating Polyneuropathy in Iran. 61
31743250 2019
38
Evidence of persistent improvements with long-term subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy. 61
31599454 2019
39
A population-based study of long-term outcome in treated chronic inflammatory demyelinating polyneuropathy. 61
31793666 2019
40
Long-term successful treatment of chronic inflammatory demyelinating polyneuropathy-like polyneuropathy induced by levodopa-carbidopa intestinal gel with intravenous immunoglobulin. 61
31330074 2019
41
Therapeutic plasma exchange in neurological disorders: Experience from a tertiary neuroscience centre. 61
31648858 2019
42
[A women with aplastic anemia developed chronic inflammatory demyelinating polyneuropathy]. 61
31761833 2019
43
An unusual case of late-infantile onset Krabbe disease with selective bilateral corticospinal tract involvement, peripheral demyelinating neuropathy, and mild phenotype. 61
30729410 2019
44
[Indication of autologous stem cell transplantation in chronic inflammatory demyelinating polyneuropathy: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. 61
31818426 2019
45
Headache and intracranial hypertension in Guillain-Barré syndrome: a case report and literature review. 61
31317792 2019
46
A Relapsing Chronic Inflammatory Demyelinating Polyneuropathy Preceding Type I Diabetes in a Young Male. 61
31857565 2019
47
Acute-onset chronic inflammatory demyelinating polyneuropathy with anti-neurofascin-155 antibodies and bilateral facial nerve enhancement. 61
31450157 2019
48
Antibody- and macrophage-mediated segmental demyelination in chronic inflammatory demyelinating polyneuropathy: clinical, electrophysiological, immunological and pathological correlates. 61
31769579 2019
49
A Severe Form of M - protein Negative Distal Acquired Demyelinating Symmetric Neuropathy. 61
31857554 2019
50
Distinctive patterns of peripheral neuropathy across the spectrum of plasma cell disorders. 61
31727997 2019

Variations for Demyelinating Polyneuropathy

Expression for Demyelinating Polyneuropathy

Search GEO for disease gene expression data for Demyelinating Polyneuropathy.

Pathways for Demyelinating Polyneuropathy

Pathways related to Demyelinating Polyneuropathy according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.21 TNFSF13B MAG AIF1
2 11.19 NFASC MAG CNTN2 CNTN1 CLDN5

GO Terms for Demyelinating Polyneuropathy

Cellular components related to Demyelinating Polyneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.9 TTR TNFSF13B PTGDS ORM1 NGF HP
2 blood microparticle GO:0072562 9.67 ORM1 HP APOA4 ALB
3 extracellular space GO:0005615 9.65 TTR TNFSF13B PTGDS ORM1 NGF HP
4 platelet alpha granule lumen GO:0031093 9.58 ORM1 GAS6 ALB
5 node of Ranvier GO:0033268 9.46 NFASC CNTN2
6 Schmidt-Lanterman incisure GO:0043220 9.43 MAG CLDN5
7 compact myelin GO:0043218 9.32 PMP22 MAG
8 anchored component of postsynaptic membrane GO:0099025 9.26 CNTN2 CNTN1
9 paranode region of axon GO:0033270 8.8 NFASC MAG CLDN5

Biological processes related to Demyelinating Polyneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell adhesion GO:0007155 9.85 NFASC MAG GAS6 CNTN2 CNTN1
2 cellular protein metabolic process GO:0044267 9.62 TTR GAS6 APOA4 ALB
3 transmission of nerve impulse GO:0019226 9.43 NFASC MAG
4 myelination GO:0042552 9.43 PMP22 NFASC CLDN5
5 high-density lipoprotein particle remodeling GO:0034375 9.4 APOA4 ALB
6 central nervous system myelination GO:0022010 9.37 MAG CNTN2
7 cerebellum development GO:0021549 9.33 FCGR2B CNTN1 AIF1
8 protein localization to juxtaparanode region of axon GO:0071205 8.96 NFASC CNTN2
9 peripheral nervous system development GO:0007422 8.8 PMP22 NGF NFASC

Molecular functions related to Demyelinating Polyneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.89 TTR TNFSF13B PTGDS PMP22 ORM1 NGF
2 lipid binding GO:0008289 9.46 NGF MAG APOA4 ALB
3 antioxidant activity GO:0016209 8.8 HP APOA4 ALB

Sources for Demyelinating Polyneuropathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....